Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma

Christopher J. Herrem, Tomohide Tatsumi, Kathleen S. Olson, Keisuke Shirai, James H. Finke, Ronald M. Bukowski, Ming Zhou, Amy L. Richmond, Ithaar Derweesh, Michael S. Kinch, Walter J. Storkus

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Whereas normally expressed at sites of cell-to-cell contact in adult epithelial tissues, recent studies have shown that the receptor tyrosine kinase EphA2 is overexpressed in numerous epithelial-type carcinomas, with the greatest level of EphA2 expression observed in metastatic lesions. In the current study, we have assessed EphA2 expression in archived renal cell carcinoma (RCC) tissues as it relates to patient disease course. Using specific anti-EphA2 monoclonal antibody 208 and immunohistochemistry, we evaluated EphA2 protein expression levels in RCC specimens surgically resected from 34 patients (including 30 conventional clear-cell RCC, 3 papillary, and 1 chromophobic RCC cases) resulting in clinical cures. Regardless of histopathologic subtype, RCC lesions expressing higher levels of EphA2 tended to be of a higher grade (P < 0.05) and larger (P = 0.093), more-highly-vascularized tumors (P = 0.005). Perhaps most notable, the degree of EphA2 overexpression (versus normal matched autologous kidney tissue) seemed predictive of short-term (<1 year) versus longer-term (>1 year) disease-free interval (P < 0.001) and of overall survival (P < 0.001) among the RCC patients evaluated. These data suggest that EphA2 expression level may serve as a useful prognostic tool in the clinical management of patients who have been successfully treated with surgery, but who are at greater risk for accelerated disease recurrence and who have a poorer prognosis.

Original languageEnglish (US)
Pages (from-to)226-231
Number of pages6
JournalClinical Cancer Research
Volume11
Issue number1
StatePublished - Jan 1 2005

Fingerprint

Renal Cell Carcinoma
Survival
EphA2 Receptor
Epithelium
Immunohistochemistry
Monoclonal Antibodies
Carcinoma
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Herrem, C. J., Tatsumi, T., Olson, K. S., Shirai, K., Finke, J. H., Bukowski, R. M., ... Storkus, W. J. (2005). Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clinical Cancer Research, 11(1), 226-231.

Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. / Herrem, Christopher J.; Tatsumi, Tomohide; Olson, Kathleen S.; Shirai, Keisuke; Finke, James H.; Bukowski, Ronald M.; Zhou, Ming; Richmond, Amy L.; Derweesh, Ithaar; Kinch, Michael S.; Storkus, Walter J.

In: Clinical Cancer Research, Vol. 11, No. 1, 01.01.2005, p. 226-231.

Research output: Contribution to journalArticle

Herrem, CJ, Tatsumi, T, Olson, KS, Shirai, K, Finke, JH, Bukowski, RM, Zhou, M, Richmond, AL, Derweesh, I, Kinch, MS & Storkus, WJ 2005, 'Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma', Clinical Cancer Research, vol. 11, no. 1, pp. 226-231.
Herrem, Christopher J. ; Tatsumi, Tomohide ; Olson, Kathleen S. ; Shirai, Keisuke ; Finke, James H. ; Bukowski, Ronald M. ; Zhou, Ming ; Richmond, Amy L. ; Derweesh, Ithaar ; Kinch, Michael S. ; Storkus, Walter J. / Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 1. pp. 226-231.
@article{4a61da21eed848008620477b72f49227,
title = "Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma",
abstract = "Whereas normally expressed at sites of cell-to-cell contact in adult epithelial tissues, recent studies have shown that the receptor tyrosine kinase EphA2 is overexpressed in numerous epithelial-type carcinomas, with the greatest level of EphA2 expression observed in metastatic lesions. In the current study, we have assessed EphA2 expression in archived renal cell carcinoma (RCC) tissues as it relates to patient disease course. Using specific anti-EphA2 monoclonal antibody 208 and immunohistochemistry, we evaluated EphA2 protein expression levels in RCC specimens surgically resected from 34 patients (including 30 conventional clear-cell RCC, 3 papillary, and 1 chromophobic RCC cases) resulting in clinical cures. Regardless of histopathologic subtype, RCC lesions expressing higher levels of EphA2 tended to be of a higher grade (P < 0.05) and larger (P = 0.093), more-highly-vascularized tumors (P = 0.005). Perhaps most notable, the degree of EphA2 overexpression (versus normal matched autologous kidney tissue) seemed predictive of short-term (<1 year) versus longer-term (>1 year) disease-free interval (P < 0.001) and of overall survival (P < 0.001) among the RCC patients evaluated. These data suggest that EphA2 expression level may serve as a useful prognostic tool in the clinical management of patients who have been successfully treated with surgery, but who are at greater risk for accelerated disease recurrence and who have a poorer prognosis.",
author = "Herrem, {Christopher J.} and Tomohide Tatsumi and Olson, {Kathleen S.} and Keisuke Shirai and Finke, {James H.} and Bukowski, {Ronald M.} and Ming Zhou and Richmond, {Amy L.} and Ithaar Derweesh and Kinch, {Michael S.} and Storkus, {Walter J.}",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "226--231",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma

AU - Herrem, Christopher J.

AU - Tatsumi, Tomohide

AU - Olson, Kathleen S.

AU - Shirai, Keisuke

AU - Finke, James H.

AU - Bukowski, Ronald M.

AU - Zhou, Ming

AU - Richmond, Amy L.

AU - Derweesh, Ithaar

AU - Kinch, Michael S.

AU - Storkus, Walter J.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Whereas normally expressed at sites of cell-to-cell contact in adult epithelial tissues, recent studies have shown that the receptor tyrosine kinase EphA2 is overexpressed in numerous epithelial-type carcinomas, with the greatest level of EphA2 expression observed in metastatic lesions. In the current study, we have assessed EphA2 expression in archived renal cell carcinoma (RCC) tissues as it relates to patient disease course. Using specific anti-EphA2 monoclonal antibody 208 and immunohistochemistry, we evaluated EphA2 protein expression levels in RCC specimens surgically resected from 34 patients (including 30 conventional clear-cell RCC, 3 papillary, and 1 chromophobic RCC cases) resulting in clinical cures. Regardless of histopathologic subtype, RCC lesions expressing higher levels of EphA2 tended to be of a higher grade (P < 0.05) and larger (P = 0.093), more-highly-vascularized tumors (P = 0.005). Perhaps most notable, the degree of EphA2 overexpression (versus normal matched autologous kidney tissue) seemed predictive of short-term (<1 year) versus longer-term (>1 year) disease-free interval (P < 0.001) and of overall survival (P < 0.001) among the RCC patients evaluated. These data suggest that EphA2 expression level may serve as a useful prognostic tool in the clinical management of patients who have been successfully treated with surgery, but who are at greater risk for accelerated disease recurrence and who have a poorer prognosis.

AB - Whereas normally expressed at sites of cell-to-cell contact in adult epithelial tissues, recent studies have shown that the receptor tyrosine kinase EphA2 is overexpressed in numerous epithelial-type carcinomas, with the greatest level of EphA2 expression observed in metastatic lesions. In the current study, we have assessed EphA2 expression in archived renal cell carcinoma (RCC) tissues as it relates to patient disease course. Using specific anti-EphA2 monoclonal antibody 208 and immunohistochemistry, we evaluated EphA2 protein expression levels in RCC specimens surgically resected from 34 patients (including 30 conventional clear-cell RCC, 3 papillary, and 1 chromophobic RCC cases) resulting in clinical cures. Regardless of histopathologic subtype, RCC lesions expressing higher levels of EphA2 tended to be of a higher grade (P < 0.05) and larger (P = 0.093), more-highly-vascularized tumors (P = 0.005). Perhaps most notable, the degree of EphA2 overexpression (versus normal matched autologous kidney tissue) seemed predictive of short-term (<1 year) versus longer-term (>1 year) disease-free interval (P < 0.001) and of overall survival (P < 0.001) among the RCC patients evaluated. These data suggest that EphA2 expression level may serve as a useful prognostic tool in the clinical management of patients who have been successfully treated with surgery, but who are at greater risk for accelerated disease recurrence and who have a poorer prognosis.

UR - http://www.scopus.com/inward/record.url?scp=19944426015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944426015&partnerID=8YFLogxK

M3 - Article

C2 - 15671550

AN - SCOPUS:19944426015

VL - 11

SP - 226

EP - 231

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -